Free Trial

Amgen (AMGN) Stock Price, News & Analysis

Amgen logo
$289.58 +1.11 (+0.38%)
Closing price 04:00 PM Eastern
Extended Trading
$289.76 +0.18 (+0.06%)
As of 05:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Amgen Stock (NASDAQ:AMGN)

Key Stats

Today's Range
$286.53
$289.89
50-Day Range
$272.44
$309.22
52-Week Range
$253.30
$339.17
Volume
1.75 million shs
Average Volume
2.83 million shs
Market Capitalization
$155.90 billion
P/E Ratio
23.68
Dividend Yield
3.29%
Price Target
$304.43
Consensus Rating
Hold

Company Overview

Amgen Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
95th Percentile Overall Score

AMGN MarketRank™: 

Amgen scored higher than 95% of companies evaluated by MarketBeat, and ranked 68th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Amgen has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 7 buy ratings, 11 hold ratings, and 2 sell ratings.

  • Amount of Analyst Coverage

    Amgen has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Amgen's stock forecast and price target.
  • Earnings Growth

    Earnings for Amgen are expected to grow by 3.73% in the coming year, from $20.62 to $21.39 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Amgen is 23.68, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 28.64.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Amgen is 23.68, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 30.41.

  • Price to Earnings Growth Ratio

    Amgen has a PEG Ratio of 2.53. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Amgen has a P/B Ratio of 26.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Amgen's valuation and earnings.
  • Percentage of Shares Shorted

    2.33% of the float of Amgen has been sold short.
  • Short Interest Ratio / Days to Cover

    Amgen has a short interest ratio ("days to cover") of 4.9.
  • Change versus previous month

    Short interest in Amgen has recently decreased by 14.83%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Amgen pays a meaningful dividend of 3.24%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Amgen has been increasing its dividend for 14 years.

  • Dividend Coverage

    The dividend payout ratio of Amgen is 77.84%. Payout ratios above 75% are not desirable because they may not be sustainable.

  • Dividend Sustainability

    Based on earnings estimates, Amgen will have a dividend payout ratio of 44.51% next year. This indicates that Amgen will be able to sustain or increase its dividend.

  • Read more about Amgen's dividend.
  • Percentage of Shares Shorted

    2.33% of the float of Amgen has been sold short.
  • Short Interest Ratio / Days to Cover

    Amgen has a short interest ratio ("days to cover") of 4.9.
  • Change versus previous month

    Short interest in Amgen has recently decreased by 14.83%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Amgen has a news sentiment score of 1.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 63 news articles for Amgen this week, compared to 40 articles on an average week.
  • Search Interest

    43 people have searched for AMGN on MarketBeat in the last 30 days. This is an increase of 10% compared to the previous 30 days.
  • MarketBeat Follows

    Only 9 people have added Amgen to their MarketBeat watchlist in the last 30 days. This is a decrease of -47% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Amgen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $810,806.00 in company stock.

  • Percentage Held by Insiders

    Only 0.69% of the stock of Amgen is held by insiders.

  • Percentage Held by Institutions

    76.50% of the stock of Amgen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Amgen's insider trading history.
Receive AMGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amgen and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AMGN Stock News Headlines

Nancy Grygiel Sells 1,267 Shares of Amgen (NASDAQ:AMGN) Stock
Amgen says FDA broadens the approved use of Repatha
“Sell Nvidia before earnings”
Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has been chasing the AI giant, Eric says its biggest customers are now its biggest competitors — and that could spell trouble ahead. Instead, he’s urging investors to consider a little-known hardware company that’s already starting to take off. In fact, while Nvidia has slipped over the past 30 days, this “off-the-radar” stock is up 18% — and Eric believes the run is just beginning.tc pixel
See More Headlines

AMGN Stock Analysis - Frequently Asked Questions

Amgen's stock was trading at $260.64 at the beginning of 2025. Since then, AMGN shares have increased by 11.1% and is now trading at $289.58.

Amgen Inc. (NASDAQ:AMGN) announced its earnings results on Tuesday, August, 5th. The medical research company reported $6.02 EPS for the quarter, beating the consensus estimate of $5.28 by $0.74. Amgen's revenue was up 9.4% compared to the same quarter last year.
Read the conference call transcript
.

The following companies are subsidiaries of Amgen: TeneoBio, Five Prime Therapeutics, Rodeo Therapeutics, Otezla, Nuevolution, Catherex, Catherex, and more.

Amgen's top institutional investors include Vanguard Group Inc. (9.98%), State Street Corp (5.45%), Geode Capital Management LLC (2.42%) and Charles Schwab Investment Management Inc. (2.39%). Insiders that own company stock include Amgen Inc, Murdo Gordon, David M Reese, Jonathan P Graham, Rachna Khosla, Nancy A Grygiel and Nancy A Grygiel.
View institutional ownership trends
.

Shares of AMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Amgen investors own include NVIDIA (NVDA), Meta Platforms (META), Chevron (CVX), Verizon Communications (VZ), Bristol Myers Squibb (BMY), JPMorgan Chase & Co. (JPM) and Advanced Micro Devices (AMD).

Company Calendar

Record date for 6/6 Dividend
5/16/2025
Ex-Dividend for 6/6 Dividend
5/16/2025
Dividend Payable
6/06/2025
Last Earnings
8/05/2025
Record date for 9/12 Dividend
8/22/2025
Ex-Dividend for 9/12 Dividend
8/22/2025
Today
8/26/2025
Dividend Payable
9/12/2025
Next Earnings (Estimated)
10/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:AMGN
CIK
318154
Employees
28,000
Year Founded
1980

Price Target and Rating

High Price Target
$383.00
Low Price Target
$195.00
Potential Upside/Downside
+5.3%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
21 Analysts

Profitability

EPS (Trailing Twelve Months)
$12.23
Trailing P/E Ratio
23.63
Forward P/E Ratio
14.03
P/E Growth
2.53
Net Income
$4.09 billion
Net Margins
18.96%
Pretax Margin
21.26%
Return on Equity
174.71%
Return on Assets
13.12%

Debt

Debt-to-Equity Ratio
7.24
Current Ratio
1.31
Quick Ratio
0.98

Sales & Book Value

Annual Sales
$33.42 billion
Price / Sales
4.66
Cash Flow
$29.91 per share
Price / Cash Flow
9.67
Book Value
$10.93 per share
Price / Book
26.46

Miscellaneous

Outstanding Shares
538,360,000
Free Float
534,647,000
Market Cap
$155.71 billion
Optionable
Optionable
Beta
0.49

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:AMGN) was last updated on 8/26/2025 by MarketBeat.com Staff
From Our Partners